JP2008510682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510682A5 JP2008510682A5 JP2007521717A JP2007521717A JP2008510682A5 JP 2008510682 A5 JP2008510682 A5 JP 2008510682A5 JP 2007521717 A JP2007521717 A JP 2007521717A JP 2007521717 A JP2007521717 A JP 2007521717A JP 2008510682 A5 JP2008510682 A5 JP 2008510682A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- och
- cycloalkyl
- compound
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 53
- 150000001875 compounds Chemical class 0.000 claims 49
- 229910052799 carbon Inorganic materials 0.000 claims 32
- 229910052757 nitrogen Inorganic materials 0.000 claims 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims 26
- 229910052760 oxygen Inorganic materials 0.000 claims 23
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- 125000003342 alkenyl group Chemical group 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- -1 aryloxyalkyl sulfonamide Chemical class 0.000 claims 11
- 229940124530 sulfonamide Drugs 0.000 claims 11
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 9
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 6
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000004104 aryloxy group Chemical group 0.000 claims 5
- 229940079322 interferon Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000014150 Interferons Human genes 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052698 phosphorus Inorganic materials 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000003949 imides Chemical class 0.000 claims 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000002777 nucleoside Substances 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 150000003456 sulfonamides Chemical class 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims 1
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950003954 isatoribine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 1
- 229950006081 taribavirin Drugs 0.000 claims 1
- 0 CCC*C(C(CC(C1)N)*1C(C(*)(*)*(*)*)=O)=N Chemical compound CCC*C(C(CC(C1)N)*1C(C(*)(*)*(*)*)=O)=N 0.000 description 4
- SGHBRHKBCLLVCI-UHFFFAOYSA-N N#Cc1cc(O)ccc1 Chemical compound N#Cc1cc(O)ccc1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 2
- VLVXVXHLNSXLAY-OMIVJXSDSA-O CC(C)CCc1nc(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4C=C)[O](Oc4ccccc4)(Oc4ccccc4)=O)=O)CN3C([C@H](C(C)(C)C)NC(OC3CCCC3)=[OH+])=O)c(ccc([O-]C)c3)c3n2)c[s]1 Chemical compound CC(C)CCc1nc(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4C=C)[O](Oc4ccccc4)(Oc4ccccc4)=O)=O)CN3C([C@H](C(C)(C)C)NC(OC3CCCC3)=[OH+])=O)c(ccc([O-]C)c3)c3n2)c[s]1 VLVXVXHLNSXLAY-OMIVJXSDSA-O 0.000 description 1
- ZSYWAFVGVGVJLG-HZUVPCQBSA-N CC(C)Nc1nc(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4C=C)C=O)=O)CN3C([C@H](C(C)(C)C)NC(OC3CCCC3)=O)=O)c(ccc(OC)c3)c3n2)c[s]1 Chemical compound CC(C)Nc1nc(-c2cc(O[C@H](C[C@H]3C(N[C@](C4)([C@@H]4C=C)C=O)=O)CN3C([C@H](C(C)(C)C)NC(OC3CCCC3)=O)=O)c(ccc(OC)c3)c3n2)c[s]1 ZSYWAFVGVGVJLG-HZUVPCQBSA-N 0.000 description 1
- XPIFPNHIJGCYJC-UHFFFAOYSA-N OCOc1cccc(Cl)c1 Chemical compound OCOc1cccc(Cl)c1 XPIFPNHIJGCYJC-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58863304P | 2004-07-16 | 2004-07-16 | |
| US60/588,633 | 2004-07-16 | ||
| US59163504P | 2004-07-27 | 2004-07-27 | |
| US60/591,635 | 2004-07-27 | ||
| PCT/US2005/025503 WO2006020276A2 (en) | 2004-07-16 | 2005-07-18 | Antiviral compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012023052A Division JP5767984B2 (ja) | 2004-07-16 | 2012-02-06 | 抗ウイルス化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008510682A JP2008510682A (ja) | 2008-04-10 |
| JP2008510682A5 true JP2008510682A5 (https=) | 2008-08-07 |
| JP5676839B2 JP5676839B2 (ja) | 2015-02-25 |
Family
ID=35447172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007521717A Expired - Fee Related JP5676839B2 (ja) | 2004-07-16 | 2005-07-18 | 抗ウイルス化合物 |
| JP2012023052A Expired - Fee Related JP5767984B2 (ja) | 2004-07-16 | 2012-02-06 | 抗ウイルス化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012023052A Expired - Fee Related JP5767984B2 (ja) | 2004-07-16 | 2012-02-06 | 抗ウイルス化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20080311077A1 (https=) |
| EP (2) | EP2316839B1 (https=) |
| JP (2) | JP5676839B2 (https=) |
| KR (1) | KR20070034119A (https=) |
| AP (1) | AP2461A (https=) |
| AR (1) | AR050174A1 (https=) |
| AT (1) | ATE516293T1 (https=) |
| AU (1) | AU2005274700B2 (https=) |
| BR (1) | BRPI0513426A (https=) |
| CA (1) | CA2571984C (https=) |
| CY (1) | CY1112453T1 (https=) |
| DK (1) | DK1778702T3 (https=) |
| EA (1) | EA200700336A1 (https=) |
| ES (1) | ES2468441T3 (https=) |
| HR (2) | HRP20110732T1 (https=) |
| IL (1) | IL180288A0 (https=) |
| MX (1) | MX2007000584A (https=) |
| NO (1) | NO20070866L (https=) |
| NZ (1) | NZ552405A (https=) |
| PL (2) | PL1778702T3 (https=) |
| PT (1) | PT1778702E (https=) |
| RS (1) | RS51974B (https=) |
| TW (2) | TW201228665A (https=) |
| WO (1) | WO2006020276A2 (https=) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| US7273851B2 (en) * | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| AU2006276246B2 (en) * | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
| ES2356776T3 (es) | 2005-10-11 | 2011-04-13 | Intermune, Inc. | Compuestos y métodos para inhibir la replicación del virus de la hepatitis. |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UA96283C2 (uk) | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| TW200819460A (en) * | 2006-07-07 | 2008-05-01 | Gilead Sciences Inc | Antiviral phosphinate compounds |
| AU2013200563C1 (en) * | 2006-07-07 | 2015-05-14 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| UA96295C2 (en) * | 2006-07-07 | 2011-10-25 | Гилиад Сайенсиз, Инк. | Antiviral phosphinate compounds |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PT2041156E (pt) | 2006-07-13 | 2014-02-21 | Achillion Pharmaceuticals Inc | Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral |
| CN101674844A (zh) * | 2006-08-04 | 2010-03-17 | 英安塔制药有限公司 | 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂 |
| US20090035271A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| EP2066688A2 (en) * | 2006-09-13 | 2009-06-10 | Novartis AG | Macrocyclic hcv inhibitors and their uses |
| AU2007309546A1 (en) * | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PL2468724T3 (pl) | 2006-12-21 | 2016-05-31 | Zealand Pharma As | Synteza związków pirolidynowych |
| US20080161254A1 (en) * | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
| BRPI0807482A2 (pt) * | 2007-02-08 | 2014-05-13 | Tibotec Pharm Ltd | Fenilcarbamatos macrocíclicos inibidores de hcv |
| WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| US20080287449A1 (en) * | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
| US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
| JP2010526834A (ja) | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤 |
| AU2014200403B2 (en) * | 2007-06-29 | 2016-05-19 | Gilead Sciences, Inc. | Antiviral compounds |
| NZ582096A (en) * | 2007-06-29 | 2012-05-25 | Gilead Sciences Inc | Antiviral compounds that inhibit hepatitis c virus (hcv) |
| WO2009005690A2 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
| AP2009005073A0 (en) | 2007-06-29 | 2009-12-31 | Gilead Sciences Inc | Antiviral compounds |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8304385B2 (en) | 2007-11-14 | 2012-11-06 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors |
| WO2009070689A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
| WO2009070692A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| TWI487522B (zh) | 2007-12-21 | 2015-06-11 | 賽基艾維洛米斯研究股份有限公司 | Ｈｃｖ蛋白酶抑制劑及其用途（一） |
| RU2515318C2 (ru) | 2007-12-21 | 2014-05-10 | Авила Терапьютикс, Инк. | Ингибиторы протеазы вируса гепатита с и их применение |
| ES2437147T3 (es) * | 2008-02-04 | 2014-01-09 | Idenix Pharmaceuticals, Inc. | Inhibidores de serina proteasa macrocíclicos |
| CN102015652A (zh) | 2008-03-20 | 2011-04-13 | 益安药业 | 作为丙型肝炎病毒抑制剂的氟化大环化合物 |
| WO2009142842A2 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2364309B1 (en) | 2008-12-10 | 2014-10-01 | Achillion Pharmaceuticals, Inc. | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| PT3309157T (pt) | 2009-05-13 | 2019-12-02 | Gilead Pharmasset Llc | Compostos antivirais |
| KR20100127948A (ko) * | 2009-05-27 | 2010-12-07 | 한국전자통신연구원 | Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용 |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| US7924650B2 (en) * | 2009-06-30 | 2011-04-12 | Oracle America, Inc. | Dynamically controlled voltage regulator for a memory |
| EP2461811B1 (en) | 2009-08-05 | 2016-04-20 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| US8927484B2 (en) * | 2009-12-03 | 2015-01-06 | Gilead Sciences, Inc. | Antiviral compounds |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| SI2640719T1 (sl) | 2010-11-17 | 2017-07-31 | Gilead Pharmasset Llc | Antivirusne spojine |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제 |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CA2835932C (en) | 2011-05-19 | 2020-03-24 | Gilead Sciences, Inc. | Processes and intermediates for preparing anti-hiv agents |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6082749B2 (ja) | 2011-11-16 | 2017-02-15 | ギリアド ファーマセット エルエルシー | 抗ウイルス化合物としての縮合イミダゾリルイミダゾール |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| EP2903988A1 (en) | 2012-10-08 | 2015-08-12 | AbbVie Inc. | Compounds useful for making hcv protease inhibitors |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
| BR112015023351A2 (pt) | 2013-03-15 | 2017-07-18 | Achillion Pharmaceuticals Inc | forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio |
| US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
| WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| US9962251B2 (en) | 2013-10-17 | 2018-05-08 | Boston Scientific Scimed, Inc. | Devices and methods for delivering implants |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
| CN109414508A (zh) | 2016-05-27 | 2019-03-01 | 吉利德科学公司 | 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法 |
| JP6989864B2 (ja) | 2017-05-05 | 2022-02-03 | ジーランド ファーマ，アー／エス | ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用 |
| SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
| JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
| CN110892989B (zh) * | 2019-06-27 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解便秘功能的副干酪乳杆菌et-22 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| ATE131825T1 (de) | 1990-06-13 | 1996-01-15 | Arnold Glazier | Phosphorylierte prodrugs |
| EP0481214B1 (en) * | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| AP1019A (en) * | 1996-10-18 | 2001-10-16 | Vertex Pharma | Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease. |
| JP3378016B2 (ja) * | 1996-12-26 | 2003-02-17 | 塩野義製薬株式会社 | カルバモイル基を有するイミダゾール誘導体の製造法 |
| ES2241157T3 (es) * | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| ES2263687T3 (es) | 2000-11-20 | 2006-12-16 | Bristol-Myers Squibb Company | Inhibidores tripeptidicos de la hepatitis c. |
| MXPA03005403A (es) * | 2001-01-31 | 2003-09-25 | Warner Lambert Co | Metodo para carbamoilar alcoholes. |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| ATE481106T1 (de) * | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2361011T3 (es) * | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
-
2005
- 2005-07-18 RS RS20110436A patent/RS51974B/sr unknown
- 2005-07-18 BR BRPI0513426-9A patent/BRPI0513426A/pt not_active IP Right Cessation
- 2005-07-18 CA CA2571984A patent/CA2571984C/en not_active Expired - Fee Related
- 2005-07-18 EP EP10178084.9A patent/EP2316839B1/en not_active Expired - Lifetime
- 2005-07-18 NZ NZ552405A patent/NZ552405A/en not_active IP Right Cessation
- 2005-07-18 MX MX2007000584A patent/MX2007000584A/es active IP Right Grant
- 2005-07-18 US US11/632,180 patent/US20080311077A1/en not_active Abandoned
- 2005-07-18 DK DK05791144.8T patent/DK1778702T3/da active
- 2005-07-18 PL PL05791144T patent/PL1778702T3/pl unknown
- 2005-07-18 EA EA200700336A patent/EA200700336A1/ru unknown
- 2005-07-18 PL PL382845A patent/PL382845A1/pl not_active Application Discontinuation
- 2005-07-18 AR ARP050102967A patent/AR050174A1/es not_active Application Discontinuation
- 2005-07-18 AU AU2005274700A patent/AU2005274700B2/en not_active Ceased
- 2005-07-18 ES ES10178084.9T patent/ES2468441T3/es not_active Expired - Lifetime
- 2005-07-18 JP JP2007521717A patent/JP5676839B2/ja not_active Expired - Fee Related
- 2005-07-18 AP AP2007003895A patent/AP2461A/xx active
- 2005-07-18 US US11/184,429 patent/US7642339B2/en active Active
- 2005-07-18 PT PT05791144T patent/PT1778702E/pt unknown
- 2005-07-18 HR HR20110732T patent/HRP20110732T1/hr unknown
- 2005-07-18 HR HR20070043A patent/HRP20070043A2/xx not_active Application Discontinuation
- 2005-07-18 EP EP05791144A patent/EP1778702B1/en not_active Expired - Lifetime
- 2005-07-18 KR KR1020077003918A patent/KR20070034119A/ko not_active Abandoned
- 2005-07-18 WO PCT/US2005/025503 patent/WO2006020276A2/en not_active Ceased
- 2005-07-18 AT AT05791144T patent/ATE516293T1/de active
- 2005-07-19 TW TW101104372A patent/TW201228665A/zh unknown
- 2005-07-19 TW TW094124376A patent/TW200614996A/zh unknown
-
2006
- 2006-12-25 IL IL180288A patent/IL180288A0/en unknown
-
2007
- 2007-02-15 NO NO20070866A patent/NO20070866L/no not_active Application Discontinuation
-
2011
- 2011-10-10 CY CY20111100970T patent/CY1112453T1/el unknown
-
2012
- 2012-02-06 JP JP2012023052A patent/JP5767984B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510682A5 (https=) | ||
| JP2009501724A5 (https=) | ||
| CA2571984A1 (en) | Antiviral compounds | |
| JP2005535574A5 (https=) | ||
| RU2013125713A (ru) | Пуринмонофосфатные пролекарства для лечения вирусных инфекций | |
| CA2409613A1 (en) | Methods and compositions for treating hepatitis c virus | |
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2010111551A (ru) | Замещенные индольные производные и способы их применения | |
| RU2005100053A (ru) | Азуленовое производное и его соль | |
| RU2008152087A (ru) | Макроциклические оксимильные ингибиторы протеазы гепатита | |
| IL307443A (en) | A short ring-modified peptide compound of proline and its use | |
| RU2014113539A (ru) | Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| CA2516018A1 (en) | Hepatitis c inhibitor peptide analogs | |
| RU2012136379A (ru) | 4'-азидонуклеозиды, активные в отношении hcv | |
| BRPI1012781A8 (pt) | N-[(2'r)-2'-deóxi-2'-fluor-2'-metil-p-fenil-5'-uridil]-l-alanina 1-metiletil éster e processo para sua produção | |
| RU2002121628A (ru) | Нуклеозидные соединения и их применение | |
| JP2005533824A5 (https=) | ||
| JP2020534374A5 (https=) | ||
| CA2540858A1 (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | |
| CA2516016A1 (en) | Hepatitis c inhibiting compounds | |
| CY1112254T1 (el) | Αρυλικοι φωσφοραμιδικοι εστερες νουκλεοζιτων και οι χρησεις τους ως αντι-ιικοι παραγοντες για την αντιμετωπιση του ιου της ηπατιτιδας c | |
| JP2005539088A5 (https=) | ||
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| EP2341065A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | |
| CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |